These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 5593769)

  • 1. [Hemochromatosis and its modern treatment].
    Böttger G
    Z Gesamte Inn Med; 1967 Jun; 22(12):376-80. PubMed ID: 5593769
    [No Abstract]   [Full Text] [Related]  

  • 2. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
    Giraud P; Orsini A; Giraud F; Pinsard N
    Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac hemochromatosis.
    Templin C; Pertschy S; Schaefer A
    Int J Cardiol; 2007 Apr; 116(3):e109-10. PubMed ID: 17134777
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hemochromatosis of the heart].
    Scieszka J; Kalina Z; Knap J
    Kardiol Pol; 1990; 33(11-2):71-6. PubMed ID: 2096256
    [No Abstract]   [Full Text] [Related]  

  • 5. [Desferal in the treatment of hemochromatosis].
    Pokora J; Matuszewski M; Sliwińska J
    Pol Tyg Lek; 1965 Aug; 20(32):1205-6. PubMed ID: 5845702
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term intraperitoneal deferoxamine for hemochromatosis.
    Swartz RD; Legault DJ
    Am J Med; 1996 Mar; 100(3):308-12. PubMed ID: 8629676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Desferrioxamine in patients with hemochromatosis and hemosiderosis].
    Maspes V; Tamigaki M; Gomes ZJ; Jamra M
    Rev Hosp Clin Fac Med Sao Paulo; 1966; 21(4):181-95. PubMed ID: 5918167
    [No Abstract]   [Full Text] [Related]  

  • 9. [Contribution to the problem of hemochromatosis].
    Bruns W; Michaelis D; Takác A; Langsch HG
    Dtsch Z Verdau Stoffwechselkr; 1966 Feb; 25(6):363-70. PubMed ID: 5998360
    [No Abstract]   [Full Text] [Related]  

  • 10. [A case of hemochromatosis treated with desferrioxamine].
    Dowzenko A; Marecik-Piasecka G; Palynyczko Z
    Pol Tyg Lek; 1967 May; 22(18):678-9. PubMed ID: 6078337
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
    Kobayashi M; Yano K; Fujisawa S
    Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of post-transfusional hemochromatosis with chelating agents].
    Delvaux D; Andrien JM; Fillet G
    Rev Med Liege; 1981 Jun; 36(11):477-80. PubMed ID: 6789438
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinically isolated cardiac hemochromatosis treated with success by desferrioxamine].
    Moretti G; Staeffen J; Galley P; Mulet M; Descamps F
    J Med Bord; 1965 Dec; 142(12):1983-6. PubMed ID: 5855516
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperpigmentation and secondary hemochromatosis: a novel treatment with extracorporeal chelation.
    Held JL; Yankiver B; Kohn SR
    J Am Acad Dermatol; 1993 Feb; 28(2 Pt 1):253-4. PubMed ID: 8432923
    [No Abstract]   [Full Text] [Related]  

  • 15. [A case of primary hemochromatosis treated with desferol].
    Lawecki J; Rogala H
    Wiad Lek; 1966 Oct; 19(19):1543-7. PubMed ID: 5977345
    [No Abstract]   [Full Text] [Related]  

  • 16. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of primary hemochromatosis with deferoxamine.
    Young N; Henry W; Nienhuis AW
    JAMA; 1979 Mar; 241(11):1152-4. PubMed ID: 762769
    [No Abstract]   [Full Text] [Related]  

  • 18. [Iron storage disease].
    Heilmeyer L
    Munch Med Wochenschr; 1967 Mar; 109(13):677-84. PubMed ID: 5631729
    [No Abstract]   [Full Text] [Related]  

  • 19. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L
    Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244
    [No Abstract]   [Full Text] [Related]  

  • 20. Change in the thyroid function by use of deferoxamine in a patient with hemochromatosis complicated by hyperthyroidism.
    Kubota K; Kurabayashi H; Tamura J; Kawada E; Tamura K; Nagashima K; Shirakura T
    J Med; 1992; 23(1):75-7. PubMed ID: 1573342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.